<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0045503</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1920</journal-id>
<journal-id journal-id-type="nlm-ta">Brain Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Res.</journal-id>
<journal-title-group>
<journal-title>Brain research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-8993</issn>
<issn pub-type="epub">1872-6240</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26581337</article-id>
<article-id pub-id-type="pmc">4865445</article-id>
<article-id pub-id-type="doi">10.1016/j.brainres.2015.11.009</article-id>
<article-id pub-id-type="manuscript">NIHMS737964</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Using hiPSCs to Model Neuropsychiatric Copy Number Variations (CNVs) has Potential to Reveal Underlying Disease Mechanisms</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Flaherty</surname>
<given-names>Erin K.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brennand</surname>
<given-names>Kristen J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Icahn School of Medicine at Mount Sinai, Department of Psychiatry, 1425 Madison Ave, New York NY, 10029</aff>
<author-notes>
<corresp id="CR1">Contact Kristen Jennifer Brennand, <email>kristen.brennand@mssm.edu</email>, phone 212.659.8259</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>12</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<day>15</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>1655</volume>
<fpage>283</fpage>
<lpage>293</lpage>
<!--elocation-id from pubmed: 10.1016/j.brainres.2015.11.009-->
<abstract>
<p id="P1">Schizophrenia is a neuropsychological disorder with a strong heritable component; genetic risk for schizophrenia is conferred by both common variants of relatively small effect and rare variants with high penetrance. Genetically engineered mouse models can recapitulate rare variants, displaying some behavioral defects associated with schizophrenia; however, these mouse models cannot recapitulate the full genetic architecture underlying the disorder. Patient-derived human induced pluripotent stem cells (hiPSCs) present an alternative approach for studying rare variants, in the context of all other risk alleles. Genome editing technologies, such as CRISPR-Cas9, enable the generation of isogenic hiPSC lines with which to examine the functional contribution of single variants within any genetic background. Studies of these rare variants using hiPSCs have the potential to identify commonly disrupted pathways in schizophrenia and allow for the identification of new therapeutic targets.</p>
</abstract>
<kwd-group>
<kwd>Schizophrenia</kwd>
<kwd>CNV</kwd>
<kwd>mouse models</kwd>
<kwd>hiPSC models</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>